ATRA — Atara Biotherapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$9.92
Market Cap$90.6M
Float4.7M
Shares Outstanding9.0M
P/E (Forward)232.56
Price/Sales (TTM)3.75
vs. Analyst Target+37.8% to analyst PT
Profit Margin-40.91%
Operating Margin (TTM)-652.91%
Revenue (TTM)$23.1M
Dividend RateNone
Analyst Target Price$13.67 (5 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $3.6M -$307M -$9.9M -$301M
2021 $20.3M -$340M $20.3M -$331M
2022 $63.6M -$228M $63.6M -$222M
2023 $8.6M -$276M -$313,000 -$266M
2024 $129M -$85.4M $108M -$75.7M
2025 $121M $32.7M $99.6M $38.6M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $17.6M $2.4M
Sep 2025 $3.5M -$4.3M
Dec 2025 $1.6M -$3.4M
Mar 2026 $516,000 -$4.1M

Ownership & Float

Insider Ownership16.7%
Institutional Ownership52.5%
Short Float11.5%

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$7.30Near-term / short-term trend
Weekly40-Week SMA$10.11Medium-term trend
Weekly80-Week SMA$9.66Cyclical trend (business cycle)
Weekly200-Week SMA$32.15Secular trend (multi-year)
Monthly10-Month SMA$10.29Near-term monthly trend
Monthly20-Month SMA$9.86Medium-term monthly trend
Monthly40-Month SMA$18.32Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$4.80 support 7.08x 0 months ago
$18.30 resistance 5.66x 4 months ago

Historical Earnings Reactions (47 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.37% -0.95% 42.55% 9.85% -6.12%
1 Day -2.21% -2.05% 34.04% 29.20% -20.82%
1 Week -0.33% -1.73% 46.81% 41.67% -29.97%
2 Weeks -0.61% -0.81% 48.94% 75.65% -70.54%
1 Month 2.81% -0.80% 47.83% 98.33% -45.74%

Next earnings: August 11, 2026 (66 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan1.3%33.3%12
Feb-5.4%33.3%12
Mar3.0%41.7%12
Apr-3.5%25.0%12
May3.5%41.7%12
Jun6.8%63.6%11
Jul0.3%63.6%11
Aug-3.0%54.5%11
Sep3.2%72.7%11
Oct-9.3%27.3%11
Nov23.3%83.3%12
Dec-6.8%33.3%12

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.30% 51.9% 547
Tuesday 0.02% 48.2% 602
Wednesday 0.07% 47.7% 599
Thursday -0.21% 47.6% 586
Friday 0.36% 48.4% 587

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 52.5%

Insider Transactions — Smart Summary

Total insider ownership: 16.7%

12-Month Insider Activity Summary

Total Filings13
Net Value-$213,404.27
Net Shares Change165,501
% of Float3.5%
C-Suite Filings8
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
EcoR1 Capital, LLC +$4.7M 1 1 buy
Panacea Innovation Ltd -$2.8M 4 2 buy, 2 sell
Nguyen AnhCo President and CEO -$63,081.921 2 2 sell
Grant-Huerta Yanina Chief Accounting Officer -$56,515.37 3 3 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-08-19 – 2025-08-20 3 3 +$615,052.712 2 C-suite
2026-05-11 – 2026-05-20 4 4 +$1.5M 2 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-05-11 EcoR1 Capital, LLC +$4.7M Transaction at $9.35, now +6.1%
2026-05-20 Nguyen AnhCo President and CEO -$47,844.565 Transaction at $9.13, now +8.7%
2026-05-20 Grant-Huerta Yanina Chief Accounting Officer -$22,036.44 Transaction at $9.13, now +8.7%
2026-05-11 Panacea Innovation Ltd -$3.2M Transaction at $10.10, now -1.8%
2026-03-04 Grant-Huerta Yanina Chief Accounting Officer -$10,690.845 Transaction at $5.08, now +95.2%
2026-03-04 Nguyen AnhCo President and CEO -$15,237.356 Transaction at $5.09, now +95.0%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Atara Biotherapeutics Inc (ATRA) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ATRA on Trend Edge →